A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-? (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C infection who failed a prior PegIFN / RBV treatment
Read time: 1 mins
Last updated:12th Apr 2011
To offer patients with virological failure in the placebo controls of the Phase III trials 1220.7, 1220.30 and 1220.47 open label treatment with BI 201335, PegIFN and RBV.
|Study start date||2011-04-12|